PharmiWeb.com - Global Pharma News & Resources
18-Feb-2019

SkinBioTherapeutics on track for development of scientifically based skin microbiome treatments (microorganisms cover the surface of the skin and maintaining the delicate balance is essential to good skin health)

FOR MEDIA INFORMATION:

Simon Vane Percy / Sarah Roberts

Vane Percy & Roberts

(T) + 44 (0) 1737 821 890

(M) + 44 (0) 7710 005 910

(e) simon@vanepercy.com

Friday 15th February 2019

SkinBioTherapeutics on track for development of scientifically based skin microbiome treatments (microorganisms cover the surface of the skin and maintaining the delicate balance is essential to good skin health)

  • Human efficacy, double blinded, study on cream formulation to read out by end of Q1
  • Discussions with leading commercial partners is proceeding
  • Study shows good moisturisation
  • Irritation study shows no irritation even at very high doses

UK based SkinBioTherapeutics is developing a range of scientifically validated treatments derived from probiotic bacteria for use in cosmetics, infection control products and for the treatment of eczema.

Led by Professor Cath O’Neill from Manchester University, a world leader in this field, the company will have the results of a double blinded, cream efficacy study in 120 volunteers in a few weeks which will be shared with interested commercial partners. This follows successful clinical studies in ensuring that the treatments do not irritate and that that they are effective moisturisers.

The skin, the body’s largest organ, is colonised by a diverse range of microorganisms which has to be managed for long term good health. SkinBioTherapeutics, patented technology, has developed a range of products based on lysates - extracts of probiotic bacteria - which will help keep the skin healthier and treat certain conditions.

The lysates work by increasing the skins barrier integrity through enhancing the formation of multi-protein complexes called 'tight junctions'. Tight junctions seal the space between adjacent cells to prevent the passage of toxins, molecules and ions through these spaces. They also help to protect the skin from infection by outcompeting harmful pathogens and increase the rate of skin healing in response to injury.

CEO Professor Cath O’Neill commented “My colleague Professor Andrew McBain and myself have been working on understanding the skin microbiome for some years. We believe that there are many treatments which could develop from our research and it has been very rewarding to have such interest from both leading commercial concerns and academia. What we believe is very important is that microbiome treatments are based on science and rigorous human studies.”

The company has also made significant progress both in the scale up of its manufacturing processes and the development of a medical device dossier for the eczema programme for submission to the regulatory authorities.

A fuller account of SkinBioTherapeutics activities is available at http://irs.nbtrader.co.uk/ir/SkinBiotix/newsArticle.php?id=2702325&ST=SBTX

Notes to editors:

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Cath O'Neill and Professor Andrew McBain.

SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin.  The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models.  Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas. 

SkinBioTherapeutics received seed funding from the Tech Transfer office of the University of Manchester for the discovery of SkinBiotix®. The platform was subsequently spun out of the University of Manchester in March 2016 and was funded by OptiBiotix PLC (AIM: OPTI).

The Company joined AIM in April 2017 concurrent with raising £4.5 million from a placing of new ordinary shares.

The Company is based in Manchester, UK. For more information, visit www.skinbiotherapeutics.com.

Editor Details

Related Links

Last Updated: 20-Feb-2019